| DC22689 |
JNJ-28610244 |
JNJ-28610244 is a potent, selective agonist of histamine H4 receptor (H4R).. |
|
| DC23567 |
JNJ303
Featured
|
JNJ303 is a potent, specific delayed rectifier potassium current I(Ks) blocker with IC50 of 64 nM, shows no effects on other cardiac channels (IC50=3.3, >10, 11.1 and 12.6 uM for Na, ICa, Ito and IKr currents). |
|
| DC8140 |
JNJ31020028
Featured
|
JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity(pIC50=8.07, human; pIC50=8.22 rat); >100-fold selective versus human Y1/Y4/Y5 receptors. |
|
| DC22405 |
JNJ-37822681 |
JNJ-37822681 is a potent, specific and fast-dissociating dopamine D2 antagonist with Ki of 158 nM. |
|
| DC8521 |
JNJ-38158471 |
JNJ-38158471(KDR) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50=40nM. It also inhibits closely related tyrosine kinases, Ret (180nM) and Kit (500nM). It has no significant activity (>1 microM) against VEGFR-1 and VEGF |
|
| DC7177 |
JNJ 38877605
Featured
|
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. |
|
| DC21440 |
JNJ-38877618 |
JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively. |
|
| DC21174 |
JNJ-38893777 |
JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain.. |
|
| DC21175 |
JNJ-38893777 sulfate |
JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain.. |
|
| DC22738 |
JNJ-39393406 |
JNJ-39393406 is a potent, selective positive allosteric α7 nAChR modulator, potentiates a 100 μM choline-induced rise in intracellular calcium mediated by human α7 channels expressed in GH4C1 cells with EC50 of 660 nM. |
|
| DC21176 |
JNJ-39729209 |
JNJ-39729209 is a potent, selective TRPV1 antagonist with binding pKi of 7.8 and 7.9 for human and rat TRPV1, respectively. |
|
| DC22750 |
JNJ-39933673 hemihydrate |
JNJ-39933673 hemihydrate is a potent, selective SGLT2 inhibitor.. |
|
| DC22751 |
JNJ-39933673 |
JNJ-39933673 is a potent, selective SGLT2 inhibitor.. |
|
| DC22683 |
JNJ-40279486 |
JNJ-40279486 is a potent, selective histamine H4 receptor antagonist with Ki of 9.4 nM (hH4), demonstrates acceptable pharmacokinetic profile and efficacy in mouse model of inflammation.. |
|
| DC21178 |
JNJ-40413269 |
JNJ-40413269 is a potent, selective, blood brain barrier (BBB) penetrant FAAH inhibitor with IC50 of 5.3 and 6.3 nM for hFAAH and rFAAH, respectively. |
|
| DC8617 |
JNJ-42041935
Featured
|
JNJ-42041935 is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes. |
|
| DC9662 |
JNJ-42165279
Featured
|
JNJ-42165279 is a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 70nM. |
|
| DC22757 |
JNJ-42314415 |
JNJ-42314415(JNJ42314415) is a potent, selective, centrally active phosphodiesterase 10A (PDE10A) inhibitor with Ki of 35 nM for human recombinant PDE10A. |
|
| DC21169 |
JNJ-42905343 |
JNJ-42905343 is a potent, selective, orally active prolyl hydroxylase (PHD) inhibitor with pKi of 8.07, 7.48 and 7.27 for PHD1, PHD2 and PHD3 respectively. |
|
| DC22125 |
JNJ4796
Featured
|
JNJ4796 (JNJ 4796, JNJ-4796) is an orally active small-molecule fusion inhibitor of influenza virus hemagglutinin (HA) with EC50 of 33 nM (H1N1 neutralization). |
|
| DC21180 |
JNJ-47965567
Featured
|
JNJ-47965567 is a potent, selective, centrally permeable P2X7 receptor antagonist with pKi of 7.9 and 8.7 for human and rat P2X7, respectively. |
|
| DC21597 |
JNJ-49095397 |
JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively. |
|
| DC23679 |
JNJ-4929821 |
JNJ-4929821 is a potent, reversible methionine aminopeptidase-2 (MetAP-2) inhibitor with IC50 of 8 nM.. |
|
| DC12166 |
JNJ-5207852
Featured
|
JNJ-5207852 is a selective and potent histamine H3 receptor (H3R) antagonist, with pKis of 8.9, 9.24 for rat and human H3R, respectively. |
|
| DC21181 |
JNJ-5234801 |
JNJ-5234801 is an atypical anxiolytic targeting 5-HT2 receptor, has demonstrated oral activity in animal models of anxiety.. |
|
| DC21170 |
JNJ525
Featured
|
JNJ525 is a small molecule inhibitor that targets tumor necrosis factor alpha (TNFα), a cytokine involved in inflammation and immune regulation. TNFα exerts its biological effects by binding to its receptors, TNFR1 (TNF receptor 1) and TNFR2 (TNF receptor 2). JNJ525 works by preventing the formation of TNFα complexes with these receptors, thereby inhibiting TNFα-mediated signaling pathways. |
|
| DC21182 |
JNJ-53718678
Featured
|
JNJ-53718678 (JNJ53718678, JNJ-678) is a potent (Kd=7.4 nM), small-molecule inhibitor of the F-glycoprotein-mediated complex membrane fusion process of the RSV. |
|
| DC12271 |
JNJ-54175446
Featured
|
JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC50s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively. |
|
| DC21183 |
JNJ-55308942 |
JNJ-55308942 is a novel highly potent P2X7 antagonist with Ki of 1.0 and 6.5 nM for rat and human hP2X7, demonstrates significant activity against a panel of related P2X receptors (P2X1, P2X2, P2X3, P2X2/3, and P2X4. |
|
| DC11229 |
JNJ-55511118 |
JNJ-55511118 (JNJ55511118) is a selective, orally available AMPA receptor containing TARP-γ8 negative modulator with Ki of 26 nM, displays no significant activity against other TARP-less AMPARs and AMPARs coexpressed with other TARPs or CNIH2. |
|
